Clinical Trials Browser

Phase NA × Gefitinib × Thoracic × Clear all

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Phase NA Unknown

NSCLC

NCT03766490 2019-01-30

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Phase NA Unknown

Non-Small-Cell Lung

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

Phase NA Unknown

Non-squamous Non-small Cell Lung Cancer

NCT03381430 2017-12-22

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Phase NA Unknown

Lung Neoplasms

NCT03157310 2017-05-17

Bone Metastasis on the Survival of Gefitinib Effective Patients

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT02282267 2017-02-24

Benefit

Phase NA Unknown

Adenocarcinoma of Lung

NCT02148380 2016-04-20

Combination of Chemotherapy and Gefitinib as First-line Treatment

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT01363557 2014-05-13

ARPEGE

Phase NA Terminated

Brain Neoplasms, Lung Neoplasms

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Phase NA Unknown

EGFR Mutation Positive Non-small Cell Lung Cancer

NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase NA Completed

CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

NCT00104728 2012-10-31

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Phase NA Terminated

42 enrolled 3 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms